Analysis of leukocyte extravasation across the blood-brain barrier: Conceptual and technical aspects

Current Allergy and Asthma Reports

Volumn 4, Issue 1, 2004, Pages 65-73

  Callahan, Melissa K ^a   Ransohoff, Richard M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; BETA CHEMOKINE; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; EPITOPE; G PROTEIN COUPLED RECEPTOR; SELECTIN; CHEMOKINE;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; CYTOKINE PRODUCTION; HEAD INJURY; HUMAN; LEUKOCYTE ACTIVATION; LEUKOCYTE MIGRATION; LIGAND BINDING; MULTIPLE SCLEROSIS; PATHOGENESIS; REGULATORY MECHANISM; RETROSPECTIVE STUDY; REVIEW; STROKE; TISSUE SPECIFICITY; CELL MOTION; FEMALE; HYPERSENSITIVITY; IMMUNE SYSTEM; IMMUNOLOGY; LEUKOCYTE; MALE; METABOLISM; NEUTROPHIL CHEMOTAXIS; PHYSIOLOGY; SENSITIVITY AND SPECIFICITY; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CELL MOVEMENT; CHEMOKINES; CHEMOTAXIS, LEUKOCYTE; FEMALE; HUMANS; HYPERSENSITIVITY; IMMUNE SYSTEM; LEUKOCYTES; MALE; SENSITIVITY AND SPECIFICITY;

EID: 2142713917     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-004-0046-9     Document Type: Review

References (65)

1. Rubin LL, Staddon JM: The cell biology of the blood-brain barrier. Annu Rev Neurosci 1999, 22:11-28.
2. Pachter JS, de Vries HE, Fabry Z: The blood-brain barrier and its role in immune privilege in the central nervous system. J Neuropathol Exp Neurol 2003, 62:593-604.
3. Aleu F, Samuels S, Ransohoff J: The pathology of cerebral edema associated with gliomas in man: report based on ten biopsies. Am J Pathol 1966, 48:1043-1061.
4. Piccio L, Rossi B, Scarpini E, et al.: Molecular mechanisms involved in lymphocyte recruitment in inflamed brain microvessels: critical roles for P-selectin glycoprotein ligand-1 and heterotrimeric G(i)-linked receptors. J Immunol 2002, 168:1940-1949.
5. Hickey WF: Leukocyte traffic in the central nervous system: the participants and their roles. Semin Immunol 1999, 11:125-137.
6. Ransohoff RM, Kivisakk P, Kidd G: Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003, 3:569-581.
7. Springer TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994, 76:301-314.
8. Butcher EC: Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991, 67:1033-1036.
9. Thureson-Klein A, Hedqvist P, Lindbom L: Leukocyte diapedesis and plasma extravasation after leukotriene B4: lack of structural injury to the endothelium. Tissue Cell 1986, 18:1-12.
10. Marchesi VT: The site of leucocyte emigration during inflammation. Q J Exp Physiol Cogn Med Sci 1961, 46:115-118.
11. Feng D, Nagy JA, Pyne K, et al.: Neutrophils emigrate from venules by a transendothelial cell pathway in response to FMLP. J Exp Med 1998, 187:903-915.
12. Middleton J, Patterson AM, Gardner L, et al.: Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 2002, 100:3853-3860.
13. Olson TS, Ley K: Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol 2002, 283:R7-R28.
14. Campbell JJ, Butcher EC: Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol 2000, 12:336-341.
15. Huising MO, Stet RJ, Kruiswijk CP, et al.: Molecular evolution of CXC chemokines: extant CXC chemokines originate from the CNS. Trends Immunol 2003, 24:307-313.
16. Murphy PM: International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol Rev 2002, 54:227-229.
17. Murphy PM, Baggiolini M, Charo IF, et al.: International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000, 52:145-176.
18. Baggiolini M: Chemokines in pathology and medicine. J Intern Med 2001, 250:91-104.
19. Huo Y, Weber C, Forlow SB, et al.: The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J Clin Invest 2001, 108:1307-1314.
20. Rollins BJ: Chemokines and atherosclerosis: what Adam Smith has to say about vascular disease. J Clin Invest 2001, 108:1269-1271.
21. Gunn MD, Tangemann K, Tam C, et al.: A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci U S A 1998, 95:258-263.
22. Forster R, Schubel A, Breitfeld D, et al.: CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999, 99:23-33.
23. Campbell JJ, Haraldsen G, Pan J, et al.: The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature, 1999, 400:776-780.
24. Soler D, Humphreys TL, Spinola SM, et al.: CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking. Blood 2003, 101:1677-1682.
25. Huang D, Han Y, Rani MR, et al.: Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulation. Immunol Rev 2000, 177:52-67.
26. Huang DR, Wang J, Kivisäkk P, et al.: Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J Exp Med 2001, 193:713-726.
27. Tran PB, Miller RJ: Chemokine receptors: signposts to brain development and disease. Nat Rev Neurosci 2003, 4:444-455.
28. Ma Q, Jones D, Borghesani PR, et al.: Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in C. Proc Natl Acad Sci U S A 1998, 95:9448-9453.
29. Zou YR, Kottmann AH, Kuroda M, et al.: Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998, 393:595-599.
30. Tsai HH, Frost E, To V, et al.: The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell 2002, 110:373-383.
31. Schwaeble WJ, Stover CM, Schall TJ, et al.: Neuronal expression of fractalkine in the presence and absence of inflammation. FEBS Lett 1998, 439:203-207.
32. Nishiyori A, Minami M, Ohtani Y, et al.: Localization of fractalkine and CX3CR1 mRNAs in rat brain: Does fractalkine play a role in signaling from neuron to microglia? FEBS Lett 1998, 429:167-172.
33. Bajetto A, Bonavia R, Barbero S, et al.: Chemokines and their receptors in the central nervous system. Front Neuroendocrinol 2001, 22:147-184.
34. Ransohoff RM: The chemokine system in neuroinflammation: an update. J Infect Dis 2002, 186(Suppl 2):S152-S156.
35. Karpus WJ: Chemokines and central nervous system disorders. J Neurovirol 2001, 7:493-500.
36. Bajetto A, Bonavia R, Barbero S, et al.: Characterization of chemokines and their receptors in the central nervous system: physicipathological implications. J Neurochem 2002, 82:1311-1329.
37. Ransohoff RM, Bacon KB: Chemokine receptor antagonism as a new therapy for multiple sclerosis. Expert Opin Investig Drugs 2000, 9:1079-1097.
38. Proudfoot AE: Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2002, 2:106-115.
39. Kivisakk P, Trebst C, Eckstein DJ, et al.: Chemokine-based therapies for MS: How do we get there from here? Trends Immunol 2001, 22:591-593.
40. Middleton J, Neil S, Wintle J, et al.: Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 1997, 91:385-395.
41. Andjelkovic AV, Spencer DD, Pachter JS: Visualization of chemokine binding sites on human brain microvessels. J Cell Bull 1999, 145:403-412.
42. Petty MA, Lo EH: Junctional complexes of the blood-brain barrier: permeability changes in neuroinflammation. Prog Neurobiol 2002, 68:311-323.
43. McGrath KE, Koniski AD, Maltby KM, et al.: Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4. Dev Biol 1999, 213:442-456.
44. Zhu Y, Yu T, Zhang XC, et al.: Role of the chemokine SDF-1 as the meningeal attractant for embryonic cerebellar neurons. Nat Neurosci 2002, 5:719-720.
45. Glabinski AR, Balasingam V, Tani M, et al.: Chemokine monocyte chemoattractant protein-1 is expressed by astrocytes after mechanical injury to the brain. J Immunol 1996, 156:4363-4368.
46. Feigelson SW, Grabovsky V, Winter E, et al.: The Src kinase p56(lck) up-regulates VLA-4 integrin affinity: implications for rapid spontaneous and chemokine-triggered T cell adhesion to VCAM-1 and fibronectin. J Biol Chem 2001, 276:13891-13901.
47. Hickey MJ, Kanwar S, McCafferty DM, et al.: Varying roles of E-selectin and P-selectin in different microvascular beds in response to antigen. J Immunol 1999, 162:1137-1143.
48. Laudanna C, Constantin G: New models of intravital microscopy for analysis of chemokine receptor-mediated leukocyte vascular recognition. J Immunol Methods 2003, 273:115-123.
49. Engelhardt B, Vajkoczy P, Laschinger M: Detection of endothelial/lymphocyte interaction in spinal cord microvasculature by intravital video microscopy. Methods Mol Med 2003, 89:83-93.
50. Johnston B, Butcher EC: Chemokines in rapid leukocyte adhesion triggering and migration. Semin Immunol 2002, 14:83-92.
51. Mackay CR: Chemokines: immunology's high impact factors. Nat Immunol 2001, 2:95-101.
52. Alon R, Feigelson S: From rolling to arrest on blood vessels: leukocyte tap dancing on endothelial integrin ligands and chemokines at sub-second contacts. Semin Immunol 2002, 14:93-104.
53. Chan JR, Hyduk SJ, Cybulsky MI: Detecting rapid and transient upregulation of leukocyte integrin affinity induced by chemokines and chemoattractants. J Immunol Methods 2003, 273:43-52.
54. Hughes PE, Oertli B, Hansen M, et al.: Suppression of integrin activation by activated Ras or Raf does not correlate with bulk activation of ERK MAP kinase. Mol Biol Cell 2002, 13:2256-2265.
55. Chigaev A, Blenc AM, Braaten JV, et al.: Real time analysis of the affinity regulation of alpha 4-integrin: the physiologically activated receptor is intermediate in affinity between resting and Mn(2+) or antibody activation. J Biol Chem 2001, 276:48670-48678.
56. Ganpule C, Knorr R, Miller JM, et al.: Low affinity of cell surface lymphocyte function-associated antigen-1 (LFA-1) generates selectivity for cell-cell interactions. J Immunol 1997, 159:2685-2692.
57. Eugenin EA, Berman JW: Chemokine-dependent mechanisms of leukocyte trafficking across a model of the blood-brain barrier. Methods 2003, 29:351-361.
58. Persidsky Y: Model systems for studies of leukocyte migration across the blood - brain barrier. J Neurovirol 1999, 5:579-590.
59. Gumbleton M, Audus KL: Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. J Pharm Sci 2001, 90:1681-1698.
60. Stins MF, Badger J, Sik KK: Bacterial invasion and transcytosis in transfected human brain microvascular endothelial cells. Microb Pathog 2001, 30:19-28.
61. Igarashi Y, Utsumi H, Chiba H, et al.: Glial cell line-derived neurotrophic factor induces barrier function of endothelial cells forming the blood-brain barrier. Biochem Biophys Res Commun 1999, 261:108-112.
62. Lee SW, Kim WJ, Choi YK, et al.: SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier. Nat Med 2003, 9:900-906.
63. Hurwitz AA, Berman JW, Rashbaum WK, et al.: Human fetal astrocytes induce the expression of blood-brain barrier specific proteins by autologous endothelial cells. Brain Res 1993, 625:238-243.
64. Hayashi Y, Nomura M, Yamagishi S, et al.: Induction of various blood-brain barrier properties in non-neural endothelial cells by close apposition to co-cultured astrocytes. Glia 1997, 19:13-26.
65. Li JN, Baskaran H, Dertinger SK, et al.: Neutrophil chemotaxis in linear and complex gradients of interleukin-8 formed in a microfabricated device. Nat Biotechnol 2002, 20:826-830.